Peptic ulcers are a category of disorders that manifest as a rupture in the intestinal epithelium that becomes saturated in acid and pepsin. It is the most frequent digestive tract disorder, with a global prevalence of 80% in developing and 40% in industrialised countries. The study aimed to compare the effectiveness and bioavailability using the in vitro dissolution method and assess other physicochemical properties of different brands of cimetidine tablets. Cimetidine is a model biopharmaceutics classification system (BCS) class-III medicine that is N-(amino sulfonyl)-3-[2 - [(diamine methylene) amino]-4-thiazolyl] methyl] thio] propanimidamide. It is a strong Histamine-2 (H2) receptor antagonist used in the treatment of peptic ulcers.
Five (5) different brands of cimetidine tablets, labelled A–E,
were purchased and used for the analysis. Physicochemical tests such as weight
uniformity, hardness, disintegration, friability, and dissolution test were
conducted following standard British pharmacopoeia procedures. Samples A-E
conformed to the weight uniformity standard with a mean % weight deviation of
0.37 – 1.39 %, while E had 11.52% based on the batch used. Samples B and A had
the highest mean kgf (10.5 and 9.7), while sample E had the lowest kgf (4.4), hence
liable to mechanical damage. All the samples used for the analysis had below
1.0% friability. All the samples passed the disintegration test, with sample A
having the longest disintegration time (4.44 minutes) and sample C having the
shortest disintegration time (0.21 minutes). At 25.99 minutes, Sample A had the
fastest disintegration rate.
The method used in the analysis is accurate, precise, and
cost-effective. The analysis does not require pretreatment of the drug and can
compete with other existing methods in the routine quality control analysis of
cimetidine in pharmaceutical formulation.
Author
(s) Details
Benjamin
U. Ebeshi
Department of Pharmaceutical and Medicinal Chemistry, Faculty of
Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria
and Department of Chemistry, Faculty of Science, Bayelsa Medical University,
Nigeria.
Samuel
J. Bunu
Department of Pharmaceutical and Medicinal Chemistry, Faculty of
Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria
and Drug Analysis and Research Center, Ebisamdex Global Ventures Ltd., Yenagoa,
Bayelsa State, Nigeria.
Ebisindor
V. Awala
Department of Healthcare Informatics, University of the Potomac,
USA.
Deghinmotei
Alfred-Ugbenbo
Department of Pharmaceutical and Medicinal Chemistry, Faculty of
Pharmaceutical Sciences, Bayelsa Medical University, Nigeria.
Adesegun
J. Kashimawo
Department of Pharmaceutical and Medicinal Chemistry, Faculty of
Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.
Seimokumo
S. Angaye
Department of Chemistry, Faculty of Science, Bayelsa Medical
University, Nigeria.
Kodilichukwu
Oliobi
Department of Pharmaceutical Chemistry, Faculty of Pharmacy,
Madonna University Elele Campus, Nigeria.
Please see the book here:- https://doi.org/10.9734/bpi/psnid/v5/4364
